ClinicalTrials.gg
CompletedNCT03750786AGENTUpdated Oct 26, 2023Results posted

A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer

A Phase 3 interventional study of Arfolitixorin and Leucovorin in Colo-rectal Cancer, sponsored by Isofol Medical AB. Completed at 94 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-26.

Sponsored by Isofol Medical AB · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
490
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,122 studies in Colonic Neoplasms with a site in United States — 116 open to participants now, 190 under way, 14 of them phase 3. Colonic Neoplasms · United States.

Enrollment
131st of 864
490 · median 50
Started
2018
with 39 others
Phase 3
81 of 1,122
6 open now
Registered
825th of 1,122
by date

Among the 1,122 studies in Colonic Neoplasms with a site in United States, this one is the 131st largest by enrollment of the 864 interventional ones that give a count, is one of 40 that started in 2018, is one of 81 in phase 3, and was the 825th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

116 of the 1,122 studies in Colonic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

111 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 328 Colonic Neoplasms studies recruiting now, 204 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,122 studies in Colonic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, parallel-group, Phase III study in at least 440 patients with advanced colorectal cancer to compare the efficacy of treatment with arfolitixorin versus Leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab according to modified FOLFOX-6 until PD according to RECIST 1.1 criteria.

03

Conditions studied

  • Colo-rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Colorectal adenocarcinoma verified by .
  2. Availability of biopsy material, from the primary tumor or , allowing for analysis of tumor gene expression.
  3. Non-resectable metastatic CRC planned for therapy with 5-FU, Leucovorin, oxaliplatin, and bevacizumab.
  4. Evaluable disease with at least one of metastatic disease (≥10 mm in longest diameter on axial image on CT-scan or alternatively MRI with \<5 mm reconstruction interval) or lymph node (≥ 15 mm in shortest axis when assessed by CT) obtained within 28 days of randomization.
  5. of more than 4 months.
  6. performance status 0 or 1.
  7. (Hb) > 80 g/L, (ANC) > 1.5x10E9/L. > 100x10E9/L.
  8. > 50 mL/min, Total \< 1.5 x , and ALT \< 3 x ULN (and \< 5 x ULN in case of liver metastases).
  9. Male or female ≥18 years of age.
  10. Female patients of must have a negative urine pregnancy test and use adequate measures . Male patients must use adequate contraceptive measures .
  11. Voluntarily signed before performance of any study related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.

Exclusion criteria

Exclusion Criteria:

  1. Malignant tumors other than colorectal adenocarcinomas (current or within the previous five years), with the exception for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix.
  2. Less than 6 months between randomization and completion of the last anti-cancer treatment (chemotherapy/radiotherapy/immunotherapy, etc.). (NB: Rectal cancer treatment shorter than 8 weeks of chemo/radiation therapy is allowed.)
  3. Confirmation of progressive disease within 6 months after completion of prior anti-cancer treatment.
  4. Indication for any Colo-rectal Cancer (mCRC) surgery or anti-cancer treatment other than study treatment.
  5. Prior treatment with arfolitixorin.
  6. Indication for treatment with a 5-FU analogue, or 5-FU for a condition other than mCRC.
  7. Known Dihydropyrimidine Dehydrogenase Deficiency (DPD) deficiency.
  8. Known or suspected central nervous system (CNS) metastases.
  9. Unresolved bowel obstruction, uncontrolled Crohn's disease, or ulcerative colitis.
  10. History of cardiac disease with a Class II or greater, congestive heart failure, myocardial infarction, or unstable angina at any time during the 6 months prior to randomization, or serious arrhythmias requiring medication for treatment.
  11. Current ≥ grade 3 diarrhea.
  12. Current chronic infection or uncontrolled serious illness causing immunodeficiency.
  13. Known or suspected or intolerance to arfolitixorin, LV, 5-FU, oxaliplatin, or bevacizumab.
  14. Breastfeeding patients.
  15. Patient who received drugs in other clinical trials within 28 days, or 5 half-lives of the investigational drug, prior to randomization.
  16. Patient with serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  17. Ongoing drug or alcohol abuse, as deemed by the Investigator.
  18. Any condition that, in the opinion of the Investigator, could compromise the patient's safety or adherence to the study protocol.
  19. Involvement, or related to people involved in the planning or conduct of the study (applies to both Isofol Medical AB (publ) staff and staff at the study site)
  20. Surgery (excluding previous diagnostic ) in the 28-day period before randomization
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
490 participants (actual)

Study arms

  • Experimental
    Group A

    ARFOX (Arfolitixorin and 5-FU and Oxaliplatin) and Bevacizumab

    Drug: Arfolitixorin

  • Active comparator
    Group B

    mFOLFOX-6 (Leucovorin and 5-FU and Oxaliplatin) and Bevacizumab

    Drug: Leucovorin

Interventions

  • Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous bolus; Arfolitixorin 60 mg/m2 intravenous bolus; 5-FU 2400 mg/m2 intravenous infusion; Arfolitixorin 60 mg/m2 intravenous bolus

  • Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; Leucovorin 400 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous infusion; 5-FU 2400 mg/m2 intravenous infusion

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Best ORR, defined as the best response recorded from the start of the study treatment until the end of treatment.

    Time frame: Until disease progression, an average of ten months

Secondary outcomes

  1. Progression Free Survival

    PFS, defined as the time from randomization to first occurrence of tumor progression based on CT-scans/MRIs.

    Time frame: Until disease progression, an average of ten months

  2. Duration of Response

    The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented.

    Time frame: Until disease progression, an average of ten months

07

Results

Posted Oct 26, 2023

Participant flow

Participant flow — Overall Study
MilestoneGroup AGroup B
Started245245
Completed00
Not completed245245

Outcome measures

PrimaryOverall Response Rate

Best ORR, defined as the best response recorded from the start of the study treatment until the end of treatment.

Time frame:
Until disease progression, an average of ten months
Reported as:
Count of participants · Participants
Overall Response Rate
ParticipantsGroup AGroup B
Complete Response25
Partial Response116116
Stable Disease10686
Progressive Disease711
Non-CR/Non-PD63
No BOR Available618
Not Evaluable26
SecondaryProgression Free Survival

PFS, defined as the time from randomization to first occurrence of tumor progression based on CT-scans/MRIs.

Time frame:
Until disease progression, an average of ten months
Reported as:
Median · months
Progression Free Survival
monthsGroup AGroup B
Progression Free Survival12.8 (10.9 to 13.2)11.6 (11.0 to 14.5)
SecondaryDuration of Response

The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented.

Time frame:
Until disease progression, an average of ten months
Reported as:
Median · months
Duration of Response
monthsGroup AGroup B
Duration of Response12.2 (11.1 to 14.1)12.9 (10.6 to 15.0)

Adverse events

Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A118/243 (48.6%)81/243 (33.3%)239/243 (98.4%)
Group B100/238 (42%)86/238 (36.1%)231/238 (97.1%)
Most frequent serious events
Showing 10 of 140
Most frequent serious events
EventGroup AGroup B
Intestinal ObstructionGastrointestinal disorders6/24310/238
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders8/2438/238
Abdominal PainGastrointestinal disorders2/2437/238
PyrexiaGeneral disorders6/2433/238
Febrile NeutropeniaBlood and lymphatic system disorders3/2435/238
Small Intestinal ObstructionGastrointestinal disorders3/2435/238
Large Intestinal ObstructionGastrointestinal disorders5/2434/238
Urinary Tract InfectionInfections and infestations1/2434/238
General Physical Health DeteriorationGeneral disorders1/2433/238
Acute Kidney InjuryRenal and urinary disorders2/2433/238
Most frequent other events
Showing 10 of 57
Most frequent other events
EventGroup AGroup B
NauseaGastrointestinal disorders117/243123/238
DiarrheaGastrointestinal disorders118/243113/238
FatigueGeneral disorders108/243103/238
Peripheral Sensory NeuropathyNervous system disorders66/24372/238
Neuropathy PeripheralNervous system disorders73/24364/238
ConstipationGastrointestinal disorders69/24364/238
Decreased AppetiteMetabolism and nutrition disorders66/24360/238
EpistaxisRespiratory, thoracic and mediastinal disorders64/24362/238
StomatitisGastrointestinal disorders52/24362/238
Neutrophil Count DecreasedInvestigations53/24362/238

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group AGroup BTotal
Mean62.4 ± 10.562.6 ± 10.762.5 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Group AGroup BTotal
Female8394177
Male162151313
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group AGroup BTotal
Hispanic or Latino000
Not Hispanic or Latino204214418
Unknown or Not Reported413172
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group AGroup BTotal
American Indian or Alaska Native000
Asian363571
Native Hawaiian or Other Pacific Islander000
Black or African American000
White179192371
More than one race000
Unknown or Not Reported301848
Time since initial diagnosis, months
Time since initial diagnosis, months(months)Group AGroup BTotal
Mean9.7 ± 20.97.7 ± 15.28.7 ± 18.1
08

Study locations

94 sites
  • 840-24 - Banner Gateway Medical Center
    Gilbert, Arizona 85234, United States
  • 840-15 - University of Southern California
    Los Angeles, California 91001, United States
  • 840-01 - HOAG Memorial Hospital
    Newport Beach, California 92663, United States
  • 840-13 - UCH-MHS d/b/a Memorial Health System
    Colorado Springs, Colorado 80909, United States
  • 840-34 - Banner MD Anderson Cancer Center
    Greeley, Colorado 80631, United States
  • 840-32 - University of Miami
    Miami, Florida 33136, United States
  • 840-08 - Pinellas Hematology Oncology
    Saint Petersburg, Florida 33709, United States
  • 840-30 - Joliet Oncology-Hematology Associates
    Joliet, Illinois 60435, United States
  • 840-06 - Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • 840-29 - Ashland-Bellefonte Cancer Center
    Ashland, Kentucky 41101, United States
  • 840-19 - University of Louisville Research Foundation Inc. (ULRF)
    Louisville, Kentucky 40202-1798, United States
  • 840-14 - University of Michigan Cancer Center
    Ann Arbor, Michigan 48109, United States
  • 840-04 - St. Vincent Frontier Cancer Center
    Billings, Montana 59102, United States
  • 840-12 - Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • 840-22 - University of Oklahoma Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • 840-10 - Oregon Health and Science University-Knight Cancer Institute
    Portland, Oregon 97239, United States
  • 840-27 - Charleston Hematology Oncology Associates
    Charleston, South Carolina 29414, United States
  • 840-02 - The University of Texas Health Science Center
    San Antonio, Texas 78229, United States
  • 036-10 - Border Medical Oncology Research Unit
    Albury, New South Wales 2640, Australia
  • 036-02 - Chris O'Brien Lifehouse
    Sydney, New South Wales 2050, Australia
  • 036-03 - Westmead Hospital
    Sydney, New South Wales 2145, Australia
  • 036-09 - Southern Medical Day Care Center
    Wollongong, New South Wales 2500, Australia
  • 036-04 - Peninsula Health - Frankston Hospital
    Frankston, Victoria 3199, Australia
  • 036-01 - Western Health - Sunshine Hospital
    Melbourne, Victoria 3021, Australia
  • 036-07 - Northern Health - Epping Hospital
    Melbourne, Victoria 3076, Australia
  • 036-05 - Monash Health
    Melbourne, Victoria 3168, Australia
  • 040-02 - Klinikum Klagenfurt am Wörthersee
    Klagenfurt, 9020, Austria
  • 040-06 - Ordensklinikum Linz GmbH - Barmherzige Schwestern
    Linz, 4010, Austria
  • 040-03 - Uniklinikum Salzburg
    Salzburg, 5020, Austria
  • 040-04 - Landesklinikum Wiener Neustadt
    Wiener Neustadt, 2700, Austria
  • 040-01 - Allgemeines Krankenhaus der Stadt Wien
    Wien, 1090, Austria
  • 040-05 - Wilhelminenspital
    Wien, 1160, Austria
  • 124-03 - William Osler Health System - Brampton Civi Hospital
    Brampton, Ontario L6R 3J7, Canada
  • 124-10 - Thunder Bay Regional Health Research Institute
    Thunder Bay, Ontario P7B 6V4, Canada
  • 124-07 - Sunnybrook Research Institute
    Toronto, Ontario M4N 3M5, Canada
  • 124-04 - CISSS de l'Outaouais - Hôpital de Gatineau
    Gatineau, Quebec J8V 2L4, Canada
  • 124-11 - CISSS de Chaudière-Appalaches
    Lévis, Quebec G6V 3Z1, Canada
  • 124-01 - Montreal University Health Center
    Montreal, Quebec H4A 3J1, Canada
  • 124-02 - Hôpital de la Cité-de-la-Santé
    Laval, H7M 3L9, Canada
  • 124-08 - Hôpital Maisonneuve Rosemont
    Montréal, H1T 2M4, Canada
  • 124-06 - Jewish General Hospital
    Montréal, H3T 1E2, Canada
  • 124-05 - Ottawa Hospital Research Institute
    Ottawa, KIH8L6, Canada
  • 250-07 - Hôpital Henri Mondor
    Créteil, 94010, France
  • 250-06 - Centre Georges Francois Leclerc
    Dijon, 21000, France
  • 250-01 - Institute Hospitalier Franco-Britannique
    Levallois-Perret, 92300, France
  • 250-09 - Hopital Privé Jean Mermoz
    Lyon, 69373, France
  • 250-08 - Hôpital Européen
    Marseille, 13003, France
  • 250-03 - Hôpital Paris Saint Joseph
    Paris, 75014, France
  • 250-02 - Hôpital Saint-Antoine
    Paris, 75571, France
  • 250-04 - Polyclinique Francheville
    Périgueux, 24000, France
  • 250-05 - Clinique Sainte Anne
    Strasbourg, 67000, France
  • 276-12 - Charité - Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • 276-02 - Universitätsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • 276-03 - Krankenhaus Nordwest GmbH
    Frankfurt am Main, 60488, Germany
  • 276-10 - Universitärers Cancer Center Hamburg (UCCH)
    Hamburg, 20246, Germany
  • 276-11 - Klinikum Kassel GmbH
    Kassel, 34125, Germany
  • 276-04 - MVZ Mitte - Onkologische Schwerpunktpraxis
    Leipzig, 04103, Germany
  • 276-13 - Universitäres Krebszentrum Leipzig (UCCL)
    Leipzig, 04103, Germany
  • 276-07 - Philipps-Universität Marburg
    Marburg, 35032, Germany
  • 276-08 - Carl von Basedow Klinikum Saalekrei GmbH
    Merseburg, 06217, Germany
  • 276-01 - Klinikum der Universität München - Campus Grosshadern
    München, 81377, Germany
  • 276-09 - Klinikum Nürnberg Nord
    Nürnberg, 90419, Germany
  • 276-05 - Kliniken Nordoberpfalz AG
    Weiden, 92637, Germany
  • 300-04 - 251 Airforce Hospital
    Athens, 11525, Greece
  • 300-01 - Aretaieo Hospital
    Athens, 11528, Greece
  • 300-02 - University General Hospital Attikon
    Athens, 15562, Greece
  • 300-03 - Metropolitan General Hospital
    Athens, 15562, Greece
  • 300-05 - Metropolitan General SA
    Athen, 15562, Greece
  • 300-06 - University General Hospital of Larissa
    Larissa, 41110, Greece
  • 392-10 - Aichi Cancer Center
    Aichi, 464-8681, Japan
  • 392-01 - National Cancer Center Hospital East
    Chiba, 277-8577, Japan
  • 392-09 - National Hospital Organization Shikoku Cancer Center
    Ehime, 791-0280, Japan
  • 392-07 - Gifu University Hospital
    Gifu City, 501-1194, Japan
  • 392-12 - Saitama Medical University International Medical Center
    Hidaka City, 350-1298, Japan
  • 392-05 - University of Tsukuba Hospital
    Ibaraki, 305-8576, Japan
  • 392-15 - Kagawa University Hospital
    Kagawa, 761-0793, Japan
  • 392-08 - St.Marianna University School of Medicine Hospital
    Kanagawa, 216-8511, Japan
  • 392-11 - National Hospital Organization Osaka National Hospital
    Osaka, 540-0006, Japan
  • 392-13 - Osaka General Medical Center
    Osaka, 558-8558, Japan
  • 392-14 - Kansai Medical University Hospital
    Osaka, 573-1191, Japan
  • 392-04 - Saitama Cancer Center
    Saitama, 362-0806, Japan
  • 392-03 - Hokkaido University Hospital
    Sapporo Hokkaido, 060-8648, Japan
  • 392-02 - Shizuoka Cancer Center
    Shizuoka, 411-8777, Japan
  • 392-06 - National Cancer Center Hospital
    Tokyo, 104-0045, Japan
  • 724-03 - Instituto Oncologico Baselga - Hospital Quiron
    Barcelona, 08023, Spain
  • 724-07 - Hospital del la Santa Creu i Sant Pau
    Barcelona, 08026, Spain
  • 724-01 - Vall d'Hebron Institute of Oncology
    Barcelona, 08035, Spain
  • 724-06 - Hospital Universitario Reina Sofia
    Córdoba, 14004, Spain
  • 724-04 - Hospital Unviersitario 12 de Octubre
    Madrid, 28041, Spain
  • 724-09 - Hospital Universitario HM Sanchinarro
    Madrid, 28050, Spain
  • 724-02 - Hospital Regional Universitario Carlos Haya
    Málaga, 29010, Spain
  • 724-05 - Hospital Universitario Virgen del Rocío
    Sevilla, 41013, Spain
  • 752-02 - Södersjukhuset
    Stockholm, 118 83, Sweden
  • 752-01 - Akademiska Sjukhuset
    Uppsala, 751 85, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Nov 2022, 47 months.

Results were first posted in Oct 2023, 11 months after primary completion.

Of 72 phase 3 interventional studies under Colonic Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 119. This study's 47 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2018
First posted
Nov 23, 2018
StartActual
Dec 18, 2018
Primary completionActual
Nov 18, 2022
CompletionActual
Nov 18, 2022
Results first posted
Oct 26, 2023
Last update
Oct 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03750786
Lead sponsor
Isofol Medical AB
Responsible party
Sponsor
First posted
Nov 23, 2018
Start date
Dec 18, 2018
Primary completion
Nov 18, 2022
Completion
Nov 18, 2022
Results posted
Oct 26, 2023
Last update
Oct 26, 2023

Study contacts

Josep Tabernero, Prof.
principal investigator · Vall d'Hebron Institute of Oncology

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: L-(+)-methylenetetrahydrofolic acid

Start the discussion